Second, our research shows that the RapidCaP-derived RCaP cells can be used as proxies for ADT- and taxane-resistant human prostate cancer cells and that they are sensitive to FABP5 inhibitors in vitro and in vivo. The gene discussed is FABP5; the disease is prostate carcinoma.